Literature DB >> 16862044

X-linked agammaglobulinemia: report on a United States registry of 201 patients.

Jerry A Winkelstein1, Mary C Marino, Howard M Lederman, Stacie M Jones, Kathleen Sullivan, A Wesley Burks, Mary Ellen Conley, Charlotte Cunningham-Rundles, Hans D Ochs.   

Abstract

X-linked agammaglobulinemia (XLA) is a primary immunodeficiency caused by mutations in the gene for Bruton tyrosine kinase (BTK) that result in the deficient development of B lymphocytes and hypogammaglobulinemia. Because the disorder is uncommon, no single institution has had sufficient numbers of patients to develop a comprehensive clinical picture of the disorder. Accordingly, a national registry of United States residents with XLA was established in 1999 to provide an updated clinical view of the disorder in a large cohort of patients. A total of 201 patients were registered by 66 physicians. The estimated birth rate for the 10-year period of 1988-1997 was 1/379,000. Infection was the most common initial clinical presentation (85%), followed by a positive family history (41%) and neutropenia (11%). Although the average age of diagnosis was younger in patients with a positive family history (mean, 2.59 yr) than in patients with a negative family history (mean, 5.37 yr) (p < 0.001), only 34.5% of patients with a positive family history at the time of their birth were diagnosed before clinical symptoms developed-that is, based on family history alone. Seventy percent of patients had at least 1 episode of otitis, 62% at least 1 episode of pneumonia, 60% at least 1 episode of sinusitis, 23% at least 1 episode of chronic/recurrent diarrhea, 21% at least 1 episode of conjunctivitis, 18% at least 1 episode of pyoderma and/or cellulitis, 11% at least 1 episode of meningitis/encephalitis, 10% at least 1 episode of sepsis, 8% at least 1 episode of septic arthritis, 6% at least 1 episode of hepatitis, and 3% at least 1 episode of osteomyelitis. Fourteen of 201 (6.9%) patients were dead at the time they were entered in the Registry. However, in a prospective 4 /4-year follow-up of living patients, only 3/80 (3.75%) patients died. Causes of death included disseminated enterovirus infection (n = 6), pulmonary insufficiency (n = 5), adenovirus infection (n = 1), sepsis (n = 1), acquired immunodeficiency disease syndrome (AIDS) (n = 1), myocarditis (n = 1), hepatitis (n = 2), and stem cell transplantation (n = 1).

Entities:  

Mesh:

Year:  2006        PMID: 16862044     DOI: 10.1097/01.md.0000229482.27398.ad

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  162 in total

1.  Increased pro-inflammatory cytokine production after lipopolysaccharide stimulation in patients with X-linked agammaglobulinemia.

Authors:  María Edith González-Serrano; Iris Estrada-García; Dolores Mogica-Martínez; Alejandro González-Garay; Gabriela López-Herrera; Laura Berrón-Ruiz; Sara Elva Espinosa-Padilla; Marco Antonio Yamazaki-Nakashimada; Alexander Vargas-Hernández; Leopoldo Santos-Argumedo; Sergio Antonio Estrada-Parra; Francisco J Espinosa-Rosales
Journal:  J Clin Immunol       Date:  2012-06-05       Impact factor: 8.317

2.  Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.

Authors:  Sylvain Thépot; Marion Malphettes; Anaëlle Gardeur; Lionel Galicier; Bouchra Asli; Lionel Karlin; Laurence Gérard; Richard Laumont; Marie-Laure Doize; Bertrand Arnulf; Claire Fieschi; Djaouïda Bengoufa; Eric Oksenhendler
Journal:  J Clin Immunol       Date:  2010-07       Impact factor: 8.317

3.  Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry.

Authors:  David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte
Journal:  Curr Opin Hematol       Date:  2020-01       Impact factor: 3.284

4.  Dermatofibrosarcoma protuberans in a patient with X-linked agammaglobulinaemia.

Authors:  P F K Yong; D Grosse-Kreul; J Maher; J R Salisbury; M A A Ibrahim
Journal:  J Clin Pathol       Date:  2007-10       Impact factor: 3.411

5.  The effects of Bruton tyrosine kinase inhibition on chemotaxis and superoxide generation in human neutrophils.

Authors:  Arnon Broides; Nurit Hadad; Jacov Levy; Rachel Levy
Journal:  J Clin Immunol       Date:  2014-04-26       Impact factor: 8.317

6.  Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation.

Authors:  M Teresa de la Morena; David Leonard; Troy R Torgerson; Otavio Cabral-Marques; Mary Slatter; Asghar Aghamohammadi; Sharat Chandra; Luis Murguia-Favela; Francisco A Bonilla; Maria Kanariou; Rongras Damrongwatanasuk; Caroline Y Kuo; Christopher C Dvorak; Isabelle Meyts; Karin Chen; Lisa Kobrynski; Neena Kapoor; Darko Richter; Daniela DiGiovanni; Fatima Dhalla; Evangelia Farmaki; Carsten Speckmann; Teresa Español; Anna Shcherbina; Imelda Celine Hanson; Jiri Litzman; John M Routes; Melanie Wong; Ramsay Fuleihan; Suranjith L Seneviratne; Trudy N Small; Ales Janda; Liliana Bezrodnik; Reinhard Seger; Andrea Gomez Raccio; J David M Edgar; Janet Chou; Jordan K Abbott; Joris van Montfrans; Luis Ignacio González-Granado; Nancy Bunin; Necil Kutukculer; Paul Gray; Gisela Seminario; Srdjan Pasic; Victor Aquino; Christian Wysocki; Hassan Abolhassani; Morna Dorsey; Charlotte Cunningham-Rundles; Alan P Knutsen; John Sleasman; Beatriz Tavares Costa Carvalho; Antonio Condino-Neto; Eyal Grunebaum; Helen Chapel; Hans D Ochs; Alexandra Filipovich; Mort Cowan; Andrew Gennery; Andrew Cant; Luigi D Notarangelo; Chaim M Roifman
Journal:  J Allergy Clin Immunol       Date:  2016-09-30       Impact factor: 10.793

7.  Clinical characteristics and genotype-phenotype correlation in 62 patients with X-linked agammaglobulinemia.

Authors:  Pamela P W Lee; Tong-Xin Chen; Li-Ping Jiang; Koon-Wing Chan; Wanling Yang; Bee-Wah Lee; Wen-Chin Chiang; Xiang-Yuan Chen; Susanna F S Fok; Tsz-Leung Lee; Marco H K Ho; Xi-Qiang Yang; Yu-Lung Lau
Journal:  J Clin Immunol       Date:  2009-11-11       Impact factor: 8.317

Review 8.  Adenoviruses in immunocompromised hosts.

Authors:  Marcela Echavarría
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

Review 9.  Primary B-cell immunodeficiencies.

Authors:  Tukisa Smith; Charlotte Cunningham-Rundles
Journal:  Hum Immunol       Date:  2018-10-22       Impact factor: 2.850

Review 10.  Successful approach to treatment of Helicobacter bilis infection in X-linked agammaglobulinemia.

Authors:  Stuart E Turvey; Sara H Leo; Annette Boos; Gregory D Deans; Julie Prendiville; Richard I Crawford; Christof Senger; Mary Ellen Conley; Peter Tilley; Anne Junker; Loretta Janz; Robert Azana; Linda Hoang; Tracy L Morton
Journal:  J Clin Immunol       Date:  2012-07-28       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.